富血小板血浆对薄型子宫内膜患者冻融周期妊娠结局的影响

目的:探讨富血小板血浆(PRP)治疗薄型子宫内膜的有效性。方法:将冷冻-解冻胚胎移植(FET)周期中子宫内膜对标准激素替代疗法(HRT)反应不良(子宫内膜厚度7mm)的92例患者分为PRP组(46例)和对照组(46例)。PRP组46例中,除HRT外,在FET周期的第13天将1ml PRP注入子宫腔。对照组46例仅接受HRT。如48h后子宫内膜厚度未能增加,则在同一周期中重复PRP灌注。子宫内膜厚度达到≥7mm时,进行胚胎移植。比较两组的子宫内膜厚度、胚胎着床率、临床和持续妊娠率。结果:与对照组相比,PRP组的子宫内膜厚度显著增加至(8.76±0.65)mm(P=0.001),胚胎着床率和临床妊娠率显著增高(分别为21.0%和40.5%)。结论:PRP可有效促进薄型子宫内膜患者子宫内膜的生长,改善妊娠结局。     

富血小板血浆促子宫内膜增殖对妊娠结局的影响

目的:探讨富血小板血浆(PRP)促子宫内膜增殖、改善薄型子宫内膜患者临床妊娠结局的应用价值。方法:选择薄型子宫内膜患者94例,其中53例予PRP治疗(PRP组),于冷冻胚胎移植周期中给予PRP宫腔内灌注治疗,另41例未予PRP治疗(对照组)。ELISA法检测PRP组中PRP与全血中血小板计数(PLT)、血小板源生长因子(PDGF)-AB、PDGF-BB及转化生长因子β(TGF-β)的表达量,并比较PRP组与对照组黄体酮日子宫内膜厚度、胚胎种植率、生化妊娠率、临床妊娠率,同时采用Logistic多变量逻辑回归分析变量因素与妊娠结局的相关性。结果:153例行PRP宫腔内灌注的患者术后均未出现不良反应,制备的PRP中PLT、PDGF-AB、PDGF-BB及TGF-β表达量均较全血中明显升高(P0.01)。2PRP组黄体酮日子宫内膜可达7.56±0.38 mm,较对照组6.41±0.36 mm明显升高,差异有统计学意义(P0.05)。PRP组生化妊娠率、临床妊娠率、胚胎种植率均比对照组明显升高(P0.05)。3Logistic回归分析结果示,子宫内膜厚度与妊娠率有关(OR 1.48,95%CI 1.04~2.21,P0.05);PRP与妊娠率有关(OR 3.16,95%CI 1.48~6.74,P0.05)。结论:制备的PRP达到治疗标准,结果满意。PRP具有促进子宫内膜增殖、改善薄型子宫内膜患者临床妊娠结局的临床效果,可作为菲薄子宫内膜的临床治疗中一种安全、有效的方法。     

宫腔灌注富血小板血浆对薄型子宫内膜不孕患者疗效的Meta分析9

目的:系统评价宫腔灌注富血小板血浆(PRP)对薄型子宫内膜不孕患者的治疗效果。方法:检索PubMed、MEDLINE、EMBASE、the Cochrane Library、Web of Science、中国生物医学数据库、万方数据库,检索时间截至2019年10月。纳入关于宫腔灌注PRP治疗薄型子宫内膜不孕患者的所有随机对照研究和队列研究,2位评价员独立完成文献筛选、资料提取,质量评价。队列研究运用改良纽卡斯尔-渥太华量表(NOS)系统评价文献质量,随机对照研究采用Cochrane偏倚风险评估工具,使用RevMan 5.2软件进行Meta分析。结果:共纳入2篇随机对照研究,2篇回顾性队列研究,1篇前瞻性队列研究,共406例,406个周期。应用宫腔灌注PRP与不采用宫腔灌注PRP比较,黄体酮转化日子宫内膜厚度(MD 1.07,95%CI 0.87～1.28,P<0.00001)、胚胎种植率(OR 2.01,95%CI 1.22～3.31,P=0.006)、血清学妊娠率(OR 2.57,95%CI 1.45～4.58,P=0.001)、临床妊娠率(OR 2.46,95%CI 1.56～3.87,P<0.0001)的差异有统计学意义,但是周期取消率、早期流产率差异无统计学意义(P>0.05)。结论:宫腔灌注PRP具有改善薄型子宫内膜不孕患者妊娠结局的临床效果,对于薄型子宫内膜不孕患者是一种安全、有效的治疗方法。     

宫腔灌注富血小板血浆对薄型子宫内膜不孕患者疗效的Meta分析

目的:系统评价宫腔灌注富血小板血浆(PRP)对薄型子宫内膜不孕患者的治疗效果。方法:检索PubMed、MEDLINE、EMBASE、the Cochrane Library、Web of Science、中国生物医学数据库、万方数据库,检索时间截至2019年10月。纳入关于宫腔灌注PRP治疗薄型子宫内膜不孕患者的所有随机对照研究和队列研究,2位评价员独立完成文献筛选、资料提取,质量评价。队列研究运用改良纽卡斯尔-渥太华量表(NOS)系统评价文献质量,随机对照研究采用Cochrane偏倚风险评估工具,使用RevMan 5.2软件进行Meta分析。结果:共纳入2篇随机对照研究,2篇回顾性队列研究,1篇前瞻性队列研究,共406例,406个周期。应用宫腔灌注PRP与不采用宫腔灌注PRP比较,黄体酮转化日子宫内膜厚度(MD 1.07,95%CI 0.87～1.28,P0.00001)、胚胎种植率(OR 2.01,95%CI 1.22～3.31,P=0.006)、血清学妊娠率(OR 2.57,95%CI 1.45～4.58,P=0.001)、临床妊娠率(OR 2.46,95%CI 1.56～3.87,P0.0001)的差异有统计学意义,但是周期取消率、早期流产率差异无统计学意义(P0.05)。结论:宫腔灌注PRP具有改善薄型子宫内膜不孕患者妊娠结局的临床效果,对于薄型子宫内膜不孕患者是一种安全、有效的治疗方法。     

富血小板血浆在改善反复种植失败患者妊娠结局中的作用

目的:评估自体富血小板血浆(PRP)改善反复种植失败(RIF)患者妊娠结局的有效性。方法:选取2018年6月至2019年7月经3次或更多次胚胎移植后仍未受孕,拟再次进行冻融胚胎移植的127例患者。将患者随机分为两组:PRP组在胚胎移植前48h宫腔灌注1ml PRP,对照组接受标准治疗。结果:两组的年龄、体质量指数(BMI)和胚胎移植次数比较,无显著差异。PRP组的子宫内膜厚度高于对照组,子宫动脉搏动指数和子宫动脉阻力指数小于对照组,PRP组的化学妊娠率、临床妊娠率高于对照组(42.8%vs 23.4%,P=0.024;39.6%vs 18.8%,P=0.011)。结论:PRP宫腔灌注有助于改善RIF患者的妊娠结局。     

麒麟丸联合芬吗通对薄型子宫内膜厚度、血流和妊娠率的影响

目的:观察麒麟丸联合芬吗通对薄型子宫内膜厚度及类型、血流和妊娠率的临床疗效。方法:前瞻性研究76例薄型子宫内膜不孕患者,随机分为对照组和研究组各38例,对照组经阴道给予芬吗通,研究组在对照组的基础上联合口服麒麟丸进行治疗。比较对照组和研究组治疗3个周期后子宫内膜厚度、类型、血流、血雌激素(E2)浓度情况和治疗半年后的自然妊娠率。结果:对照组和研究组治疗3个周期后的子宫内膜厚度、类型、血流、E2浓度情况均有明显改善(P0.05),且研究组子宫内膜厚度和血流优于对照组,差异均有统计学意义(P0.05);治疗半年后自然妊娠率研究组显著高于对照组(52.6%vs 28.9%),差异有统计学意义(P0.05);研究组和对照组中妊娠患者子宫内膜厚度、类型、血流分别与本组中未妊娠患者比较,差异均有统计学意义(P0.05)。结论:麒麟丸联合芬吗通治疗因子宫内膜薄而致的不孕,可有效改善子宫内膜厚度及血流,提高治疗半年后的自然妊娠率。     

促排卵过程中子宫内膜厚度变化对IVF-ET结局的影响

目的:探讨促排卵过程中子宫内膜厚度变化趋势对IVF结局的影响,以及不同促排卵方案对子宫内膜厚度变化趋势的影响。方法:回顾性分析1 173个IVF-ET周期,控制性促排卵方案包括:长方案(568例)、口服避孕药(OC)+GnRHa方案(425例)、拮抗剂方案(107例)和超长方案(73例)。比较各种促排卵方案的妊娠组与非妊娠组的子宫内膜厚度变化情况,包括Gn启动当日、启动后第5日、hCG注射日及子宫内膜差值1(=启动后第5日内膜厚度-启动当日内膜厚度)、子宫内膜差值2(=hCG注射日内膜厚度-启动后第5日内膜厚度)、子宫内膜差值3(=hCG注射日内膜厚度-启动当日内膜厚度)。结果:hCG注射日子宫内膜厚度妊娠组均较未妊娠组显著增加(P<0.05);Gn启动当日子宫内膜厚度、促排卵第5日子宫内膜厚度、子宫内膜厚度差值1、差值2、差值3妊娠组与未妊娠组间均无统计学差异(P>0.05)。结论:促排卵过程中子宫内膜厚度的变化趋势不能预测IVF结果,不同的促排卵方案不影响子宫内膜厚度的变化趋势。     

阴道超声评估不孕妇女子宫内膜容受性的价值研究

目的:探讨阴道超声评估子宫内膜容受性的价值。方法:对1680例处于排卵期的不孕症患者,应用阴道超声检测卵泡大小、内膜厚度,并按照内膜超声图像分为A、B、C3型,将子宫内膜厚度、类型与妊娠结局进行对照分析。结果:A型内膜占66.07%,妊娠率12.61%;B型内膜占25.00%,妊娠率9.52%;C型内膜占8.93%,妊娠率6.67%。各组成功妊娠的内膜类型以A型为主,占73.68%(140/190)。不同子宫内膜类型的妊娠率差异有统计学意义,两两比较表明,A型妊娠率高于C型(χ2=4.4546,P=0.0348),差异有统计学意义,A型与B型及B型与C型的妊娠率均无统计学差异(χ2值及P值分别为2.8005、0.0942及2.2883、1.1275)。按A型子宫内膜厚度不同分为5组,其中厚度在8～10.9mm妊娠率最高,妊娠例数占总妊娠例数的92.86%(130/140),高于厚度<8mm组和>11mm组,差异有统计学意义。按B型子宫内膜厚度不同分为5组,其中7～8.9mm组妊娠率高于其余各组,差异有统计学意义。结论:子宫内膜适合着床的理想厚度是8～10.9mm,A型内膜更适合着床。阴道B超监测子宫内膜类型与厚度在评估内膜容受性、指导临床调整用药及自然受孕或人工助孕等方面有主要价值。     

子宫内膜厚度、β-HCG和孕酮联合检测对异位妊娠与早早孕诊断价值的探讨

目的:探讨异位妊娠与早早孕鉴别诊断的特征性依据,避免误诊误治。方法:对132例疑似异位妊娠的病例测量子宫内膜厚度及测定血清-βHCG及孕酮值。结果:本研究的所有病例血清-βHCG及孕酮值高于正常非妊娠者。但宫内妊娠组子宫内膜厚度及孕酮值明显大于异位妊娠组,P<0.01;正常宫内妊娠的子宫内膜厚度、-βHCG及孕酮值大于宫内妊娠流产组。结论:血清-βHCG及孕酮值是确定妊娠的指标,但难以鉴别异位妊娠和尚未形成宫内孕囊的早早孕及宫内妊娠流产,结合子宫内膜厚度则能预测妊娠的趋向,提示妊娠的着床部位,为防止误诊提供了一个有价值的临床早期诊断指标。     

hCG日子宫内膜厚度与体外受精-胚胎移植妊娠结局多中心回顾性研究

目的探讨h CG日子宫内膜厚度对体外受精-胚胎移植(IVF-ET)妊娠结局的影响。方法纳入2015-01-01—2015-12-31 8家生殖中心共3601个IVF-ET周期。在h CG注射日测量子宫内膜厚度,绘制子宫内膜厚度与助孕结局的分布表,根据子宫内膜厚度分为2组,A组(289个周期):h CG日子宫内膜厚度8mm,B组(3312个周期):h CG日子宫内膜厚度≥8mm。比较两组临床妊娠率、活产率、妊娠丢失率、单胎妊娠持续时间、单胎出生体重。结果 A、、47.0%(P=0.000),妊娠丢失率分别为23.3%、15.8%(P=0.024)。两组单胎分娩胎儿妊娠持续时间和单胎分娩胎儿体重比较差异无统计学意义。采用多因素logistic回归校正女方年龄、BMI、移植胚胎数后,B组与A组比较,临床妊娠率(a OR=1.492,P=0.001)与活产率(a OR=1.621,P=0.000)均增加。结论 h CG日子宫内膜厚度影响IVF-ET妊娠结局,子宫内膜厚度8mm时,IVF-ET的临床妊娠率与活产率较低,在患者进行移植策略决策时,应充分告知;但h CG日子宫内膜厚度不影响单胎妊娠的妊娠持续时间和胎儿出生体重。     

Evaluation of granulocyte colony-stimulating factor on the treatment of thin endometrium during frozen-thawed embryo transfer cycles: a retrospective cohort study

Abstract

The aim of this study was to evaluate the effect of granulocyte colony-stimulating factor (G-CSF) on thin endometrium (≤7?mm) in women undergoing frozen-thawed embryo transfer (FET). This retrospective cohort study includes 271 infertile patients with thin endometrium. 117 patients who received intrauterine perfusion of G-CSF before the day of administration of progesterone were defined as G-CSF group, whereas 154 patients who refused to use G-CSF treatment were defined as control group. In the G-CSF group, significantly higher endometrial thickness was observed after G-CSF perfusion (p?<?.001). When we divided the G-CSF group into two subgroups according to whether they conceived, the endometrial thickness increased from 6.02?±?0.92?mm to 6.98?±?1.20?mm in the conception group (p?<?.001) and from 6.21?±?0.96?mm to 6.87?±?1.16?mm in the non-conception group (p?<?.001). However, there were no significant differences between the two subgroups in respect to the endometrial thickness both before and after G-CSF perfusion. The implantation rate, hCG positive rate and clinical pregnancy rate were similar between G-CSF group and control group. Thus, our study fails to demonstrate that G-CSF has the potential to improve pregnancy outcome but has the potential to increase endometrial thickness of the women with thin endometrium in FET cycles.     

薄型子宫内膜合并甲状腺功能减退不孕患者的辅助生育治疗结局

目的探讨薄型子宫内膜合并甲状腺功能减退不孕患者行辅助生育治疗后的效果。方法 165例因新鲜周期内膜≤7 mm而取消胚胎移植的不孕患者,在拟行冻融胚胎移植前,对游离甲状腺素T4(FT4)正常、促甲状腺激素(TSH)2.5 mIU/L的患者进行左旋甲状腺素片干预治疗。经治疗4~8周后,患者依据TSH水平分为A组(n=70),TSH2.5 mIU/L;B组(n=95),TSH≤2.5 mIU/L。所有患者均采用相同剂量激素替代方案准备子宫内膜,分析子宫内膜情况及辅助生育结局。结果 A组与B组相比,虽然子宫内膜下血流数量和阻力指数(RI)组间无统计学差异(P0.05),但B组内膜下血流数量的均值高于A组,RI均值低于A组。且B组的子宫内膜厚度、临床妊娠率显著高于A组(P0.05),流产率显著低于A组(P0.05)。结论薄型子宫内膜合并TSH升高的不孕患者,给予干预至TSH2.5 mIU/L后,行辅助生育治疗可改善这些患者的妊娠结局。     

不孕症合并子宫内膜非典型增生患者助孕治疗的临床分析

目的探讨不孕症合并子宫内膜非典型增生患者经保守治疗后助孕治疗的疗效和安全性。方法回顾性分析8例不孕症合并子宫内膜非典型增生患者，经孕激素或促性腺激素释放激素激动剂（GnRHa）治疗子宫内膜非典型增生缓解后，采用助孕治疗，观察助孕治疗的疗效及其对子宫内膜的影响。结果经孕激素或GnRHa治疗后，8例患者子宫内膜非典型增生全部缓解。共进行单纯促排卵治疗7个周期，促排卵联合人工授精2个周期，体外受精-胚胎移植（IVF—ET）7个周期，冻融胚胎移植2个周期。单纯促排卵周期均未妊娠，人工授精1个周期双胎妊娠；7个IVF—ET周期中，胚胎移植6个周期，3个周期获得临床妊娠；冻融胚胎移植1个周期获得临床妊娠。现足月分娩6活婴。1例未妊娠患者在促排卵后4个月发现子宫内膜癌变。结论不孕症合并子宫内膜非典型增生的患者经孕激素或GnRHa治疗缓解后，及时助孕治疗能提高妊娠率，但需严密观察，注意子宫内膜癌发生的可能。     

Prospective evaluation of the ultrasound appearance of the endometrium in a cohort of 1,186 infertile women

OBJECTIVE: To investigate the effect of differences in endometrial thickness and pattern as visualized with present-day high-resolution transvaginal ultrasound equipment on the outcome of assisted reproductive treatment. DESIGN: Prospective cohort study. SETTING: Two large infertility units in university hospitals. PATIENT(S): The endometrial characteristics of 981 patients during 1,600 assisted reproductive treatment cycles were compared with those of 205 untreated women. In addition, abnormal echogenic patterns of the endometrium were characterized histologically in 44 patients. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Pregnancy rates. RESULT(S): The endometrium was significantly thinner in untreated women and women treated with IUI than in women treated with IVF or intracytoplasmic sperm injection. The exponential proliferation of the endometrium was similar in conception and nonconception cycles. The odds for a successful pregnancy were significantly lower in the presence of a thin endometrium in women treated with IUI but not in women treated with the long stimulation protocol for IVF or intracytoplasmic sperm injection. Singleton pregnancies were more common than multiple pregnancies in patients with thin endometria. CONCLUSION(S): The pregnancy rates of assisted reproductive procedures are influenced only marginally by the degree of endometrial proliferation, and treatment should not be canceled because of inadequate endometrial thickness.     

Can autologous platelet rich plasma expand endometrial thickness and improve pregnancy rate during frozen-thawed embryo transfer cycle? A randomized clinical trial

Objective

One of the important aspects involved in achieving optimal outcomes after assisted reproductive treatment (ART) is the endometrium. Some cycles are cancelled due to inadequate endometrial growth in ART. In this clinical trial, we evaluated the effectiveness of platelet-rich plasma (PRP) in the treatment of thin endometrium.

Extended estrogen administration for women with thin endometrium in frozen-thawed in-vitro fertilization programs

Purpose: To evaluate the effect of extended estrogen administration for women with thin endometrium in frozen-thawed in-vitro fertilization (IVF) programs. Methods: Thirty-six women undergoing IVF program had thin endometrium (<8 mm). Among them, 23 received fresh embryo transfer (control group), but 13 canceled embryo transfer and underwent frozen-thawed embryo transfer in the subsequent cycle after extended administration of exogenous estrogen (study group). Results: In the study group, the mean endometrial thickness increased significantly from 6.7 mm in controlled ovarian hyperstimulation cycles to 8.6 mm after an extended estrogen therapy for 14 to 82 days (P=0.031). Their pregnancy rate was significantly higher than that in the control group (38.5% vs. 4.3%, P=0.016). Among 5 women achieving pregnancies in the study group, one was complicated with placenta accreta, and the other 4 had uneventful pregnancies. Conclusions: Extended estrogen administration followed by frozen-thawed IVF programs is beneficial for women with thin endometrium. However, the risk of abnormal placentation and peripartal complication should be kept in mind.     

Improved in vitro fertilization success and pregnancy outcome with autologous platelet-rich plasma treatment in unexplained infertility patients that had repeated implantation failure history

Repeated implantation failure (RIF) due to suboptimal endometrial lining is a major challenge in reproductive medicine. The study aims to evaluate effect of intrauterine platelet-rich plasma (PRP) treatment on frozen-thawed embryo transfer (FET) cycles in patients whose endometrium was unable to achieve optimal lining in unexplained infertility patients with history of RIF. We retrospectively analyzed the charts of a total of 302 cycles performed in 273 patients attending Diyar Life ART Centre between January 2014 and January 2017. After excluding 232 cycles, we compared pregnancy outcomes of 34 patients who had suboptimal endometrial lining and underwent PRP?+?FET and 36 patients who had optimal endometrial lining and underwent only FET. We observed that, endometrial thickness was higher after 48?hours from PRP when compared to endometrial thickness before PRP (10?mm vs. 6.25?mm, p?<?.001). Clinical pregnancy rate, and importantly live birth rate were also significantly higher in PRP group than the control group. Based on this information, we showed that intrauterine autologous PRP infusion is a safe, inexpensive adjuvant treatment for optimizing endometrium especially in patients with RIF history and intrauterine PRP infusion improved not only endometrial lining but also in vitro fertilization success and pregnancy outcome.     

Management of thin endometrium in assisted reproduction: a clinical practice guideline from the Canadian Fertility and Andrology Society

The impact and management of thin endometrium is a common challenge for patients undergoing assisted reproduction. The objective of this Canadian Fertility and Andrology Society (CFAS) guideline is to provide evidence-based recommendations using the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework on the assessment, impact and management of thin endometrium in assisted reproduction. The effect of endometrial thickness on pregnancy and live birth outcomes in ovarian stimulation and IVF (fresh and frozen cycles) is addressed. In addition, recommendations on the use of adjuvants to improve endometrial thickness and pregnancy outcomes are provided.     

近排卵期高回声子宫内膜及干预对子宫内膜异位症患者体外受精结局的影响

目的:评价近排卵期高回声子宫内膜及干预对子宫内膜异位症(内异症)患者体外受精(IVF)结局的影响。方法:内异症性不孕患者142例(147个周期),IVF前阴道B超监测自然周期子宫内膜,以近排卵期出现高回声子宫内膜患者为研究组,根据是否干预内膜再分成干预组(39例,42个周期)和未干预组(19例,19个周期);以内膜形态正常患者为对照组(84例,86个周期)。分析3组IVF结局。结果:干预组种植率及临床妊娠率高于未干预组及对照组(P<0.05);未干预组种植率低于对照组(P<0.05),临床妊娠率低于对照组(分别为15.8%及36.0%),但差异无统计学意义;干预组与未干预相比,HCG日内膜异常形态比率显著降低(P<0.05);干预组与对照组相比,HCG日内膜异常比率高,A型内膜比率低,B型内膜比率显著升高(P<0.05);未干预组与对照组相比,HCG日异常内膜比率高,A型及B型内膜比率低(P<0.05)。结论:内异症患者自然周期近排卵期出现高回声子宫内膜可降低IVF种植率及临床妊娠率,干预后可改善内膜形态及IVF结局。     

Relationships between pregnancy rates following in vitro fertilization or intracytoplasmic sperm injection and endometrial thickness and pattern

OBJECTIVE: To investigate the role of endometrial thickness and pattern on the day of human chorionic gonadotropin (hCG) administration on in vitro fertilization (IVF)/intracytoplasmic injection (ICSI) outcome. STUDY DESIGN: A total of 150 infertile women undergoing embryo transfer after IVF/ICSI cycles were studied in a prospective survey. Sonographic features of the endometrium (thickness and pattern) on the day of hCG administration, hormonal profile (progesterone, estradiol, FSH, LH) and various other variables (maternal age, causes and duration of infertility, duration of treatment, number of human menopausal gonadotropin (hMG) ampoules administered, and number of oocytes retrieved) were evaluated. These variables in pregnant and nonpregnant patients were compared. RESULTS: There was no difference between pregnant and nonpregnant patients in mean endometrium thickness (10.1+/-1 versus 10.2+/-2, p=0.79). Pregnancies occurred only in patients with an endometrial thickness of 9-12 mm (p=0.036). Duration of treatment, number of hMG ampoules administered, number of oocytes retrieved, estradiol concentration, and estradiol/progesterone ratio on the day of hCG differed significantly between pregnant and nonpregnant patients. There was no correlation between endometrial pattern and pregnancy rate. The receiver-operating characteristic (ROC) curve and multiple logistic regression showed no significant effect of endometrial thickness in the outcome of IVF/ICSI. CONCLUSION: The sonographic features of the endometrium (thickness and pattern) on the day of hCG administration did not differ between pregnant and nonpregnant patients. The pregnancy rate declined beyond two limits of endometrial thickness.